Generic Portal

— Research Explorer

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

Research output: Contribution to journal › Article › Academic › peer-review

MEK, b-cell lymphoma 2 (BCL-2), navitoclax (ABT-263, PubChem CID: 24978538), neuroblastoma, pediatric cancer, synergy, trametinib (PubChem CID: 11707110), venetoclax (ABT-199, PubChem CID: 49846579)

ID: 34540878